Special Issue "Drug Discovery and Development Targeting NMDA Receptors"
Deadline for manuscript submissions: 15 February 2024 | Viewed by 760
Interests: NMDA receptors; drug discovery; pharmaceutical profiling; drug targeting; Alzheimer’s disease
Special Issues, Collections and Topics in MDPI journals
Excitement in the NMDA receptor antagonist field was rekindled by the USA FDA approval of Memantine for the treatment of Alzheimer’s disease in 2003. This special issue is a follow on of our special issue of a decade ago titled “NMDA Receptor Antagonists for the Treatment of CNS Disorders” in this journal. As predicted then, there have been several positive developments in the field and thus a revised look is warranted. An example is the approval of NMDAR antagonist ketamine for treatment resistant depression. It represents a new mechanism for treatment of depression in over 3 decades. Another antagonist, Dextromethorphan has been approved for depression. Other NMDAR antagonists are being examined for treatment of pain. While all glutamate receptors are possible drug targets, the NMDA receptor has been particularly attractive for many reasons, including feasibility and possible options of use. The goal of this special issue is to examine progress in, current and future prospects in CNS drug discovery through this receptor.
Prof. Dr. Adeboye Adejare
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- NMDAR antagonist
- CNS drug discovery
- neuropathic pain
- memory and learning
- ionotropic receptors